Skip to main content
v2026.11,986 entries · CC-BY 4.0

Editorial · CASRAI · Clinical research and clinical trials

FDA approves Regeneron’s Livsayis, first siRNA therapy for AChR-positive myasthenia gravis

FDA approved Regeneron’s Livsayis (cemdisiran) on 18 November 2026 for adults with AChR antibody-positive generalized myasthenia gravis.

Published 19 Nov 2026· 7 minute read
A set of laboratory pipettes of the kind used in molecular biology work, shown as general background
Photo: Jucember / Wikimedia Commons, CC BY-SA 3.0 (cropped). Source · Licence

The US Food and Drug Administration approved Regeneron Pharmaceuticals’ Livsayis (cemdisiran) on Wednesday 18 November 2026 for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. Regeneron describes it as the first and only approved small interfering RNA (siRNA) therapy for gMG, and the approval rests on the Phase 3 NIMBLE trial, registered as NCT05070858. For researchers, it is a regulatory test case for RNA interference aimed at the complement pathway, and for research offices it brings a risk programme that trial sites will recognise.

What happened

Regeneron announced the approval on 18 November 2026, and the Muscular Dystrophy Association (MDA) published its own release the same day. According to the MDA release, Livsayis is a complement component 5 (C5)-directed siRNA designed to reduce C5 production, with the aim of lessening immune-mediated damage at the neuromuscular junction. The MDA release states that it is the first and only FDA-approved siRNA therapy for gMG.

The approval follows a short regulatory path. NeurologyLive reported on 22 June 2026 that the FDA had accepted Regeneron’s new drug application under priority review, which followed the use of a priority review voucher, with a target action date in November 2026. The decision arrived inside that month.

Regeneron’s own estimate, reported by AJMC on 19 November 2026, is that about 85,000 people in the United States have gMG. The MDA release gives a prevalence for myasthenia gravis of roughly 37 people per 100,000 in the US.

Key details

The facts below come from the approval coverage and the trial registry. They are reported as the sources state them and are not a substitute for the FDA label.

Item As reported
Product Livsayis (cemdisiran), a C5-directed siRNA from Regeneron
Indication Adults with anti-AChR antibody-positive generalized myasthenia gravis
Approval announced 18 November 2026
Pivotal study NIMBLE, Phase 3, randomized, double-blind, placebo-controlled, NCT05070858
Trial sponsor Regeneron Pharmaceuticals
Registry enrolment 288 participants (actual), status active, not recruiting
Primary endpoint Change from baseline in MG-ADL score at week 24
Access programme Livsayis REMS, with provider enrolment and patient counselling
EU status Application under review; decision expected in the second half of 2027

What NIMBLE measured

The ClinicalTrials.gov record for NCT05070858 lists the study as a Phase 3 trial of pozelimab and cemdisiran combination therapy and cemdisiran monotherapy in patients with symptomatic generalized myasthenia gravis, sponsored by Regeneron, with 288 participants enrolled. AJMC reports that the trial was randomized, double-blind and placebo-controlled, with arms for cemdisiran alone, cemdisiran plus pozelimab, pozelimab alone and placebo, and that background immunosuppressants were allowed. NeurologyLive adds that eligible adults had symptomatic, AChR antibody-positive disease and that treatment ran for 24 weeks. The approval covers only the AChR-positive population.

At week 24, the AJMC and NeurologyLive reports agree on the headline numbers. The Myasthenia Gravis Activities of Daily Living (MG-ADL) score improved by 4.5 points with cemdisiran and by 2.2 points with placebo, a placebo-adjusted difference of 2.3 points. A 3-point or greater improvement was reached by 76.6% of cemdisiran-treated patients against 44.1% on placebo. On the Quantitative Myasthenia Gravis (QMG) score, the key secondary endpoint, improvement was 4.2 points against 1.5 points, a difference of 2.8 points, and 48.4% against 19.0% reached an improvement of 5 points or more. AJMC adds that improvement began as early as 2 weeks. The cemdisiran-plus-pozelimab arm improved by 4.0 points on MG-ADL and showed no numerical advantage over cemdisiran alone. The results were published in The Lancet in 2026 and presented at the American Academy of Neurology annual meeting in April 2026.

Safety information in the label coverage

AJMC reports that the label carries a boxed warning for serious meningococcal infections caused by Neisseria meningitidis, that patients are to carry a safety card, and that the product is available only through the Livsayis REMS. Common adverse reactions reported for the label were injection-site reactions, viral infections and urinary tract infections. Serious infections occurred in 5% of cemdisiran-treated patients across the pivotal study and its extension, including one fatal pneumonia during the extension. NeurologyLive’s earlier report on the double-blind period noted no meningococcal infections or deaths in that phase, and that the one death occurred in the extension in a patient with significant comorbidities and concomitant immunosuppressive therapy. Pregnancy data are limited, and pediatric safety and effectiveness have not been established.

Background and context

Complement C5 is already a target in gMG, and the MDA release notes that recent targeted therapies include complement inhibitors and neonatal Fc receptor (FcRn) inhibitors. What distinguishes cemdisiran, according to NIMBLE principal investigator Tuan Vu of the University of South Florida, is the route: unlike existing C5 inhibitors that act directly on the C5 molecule, it works by preventing the hepatic production of C5. Gil Wolfe, co-director of the MDA Care Center at the University at Buffalo, described the same idea in the MDA release as using a novel mechanism “to block at an RNA level the actual synthesis of a complement component.”

For research readers, the combination arm is as informative as the monotherapy result. Vu said at AAN 2026, as reported by NeurologyLive, that cemdisiran alone showed meaningful efficacy while adding pozelimab, an anti-C5 antibody, gave no incremental benefit. A trial that tests a production blocker against a production blocker plus a circulating-protein blocker, and reports that the combination added nothing, is a useful design reference for other complement-pathway programmes.

Reaction

MDA Chief Research Officer Angela Lek said that the approval of new targeted therapies “has expanded options for the myasthenia gravis (MG) community.” Bhaskar Roy, an MDA Care Center director and Yale neurology associate professor, said that “as treatment options continue to expand, it is essential that people living with MG work closely with their care teams.” Vu, quoted by AJMC, said the NIMBLE results showed “rapid, deep disease control maintained through the end of dosing intervals.”

What it means for researchers, universities and research offices

RNAi in a complement target. An approved siRNA that suppresses a liver-produced complement component gives investigators in complement biology and RNA interference a regulatory precedent for this mechanism in an autoimmune neuromuscular disease. Groups proposing similar approaches can now point to an FDA-approved example when they describe their translational path, while the label’s boxed warning shows what the agency expects to see managed when complement is suppressed.

Trial registration and transparency. NIMBLE is a worked example of a registered Phase 3 trial: a public ClinicalTrials.gov record, a peer-reviewed Lancet paper published alongside the conference presentation, and an approval that cites the same programme. Research offices that audit registration and results-reporting compliance can use the record as a reference for what a complete trail looks like. Note that registry enrolment (288) and the analysed population described in coverage are different counts, so cite the source for any figure you quote.

REMS and site operations. Because the product is available only through a Risk Evaluation and Mitigation Strategy that requires provider enrolment and patient counselling, institutions that treat or study gMG patients, including hospital pharmacies and neuromuscular clinics, will need to decide who enrols and who documents the counselling. Sites running other gMG studies should review whether the newly approved comparator changes eligibility criteria, rescue-therapy rules or background-therapy allowances in their protocols.

Post-marketing obligations. Every approved new drug application carries postmarketing adverse-experience reporting duties under 21 CFR 314.80. The coverage identifies the REMS and the safety card as the ongoing requirements for Livsayis; any further commitments will sit in the FDA approval documents, which research offices supporting sponsor-investigator or extension studies should read directly.

Regulatory timing as a planning data point. The sequence of acceptance, priority review and a November 2026 PDUFA target, followed by an action within that month, is a concrete timeline that regulatory-affairs staff and sponsors can use when scoping their own submissions.

What happens next

The European Medicines Agency has accepted the marketing authorisation application, and NeurologyLive reports that a European Commission decision is anticipated in the second half of 2027. Regeneron also said in June that a regulatory submission in Japan is planned for early 2027. AJMC reports that no US launch date or pricing has been announced, and that Regeneron operates a programme, myRARE, for insurance benefit verification and information on potential financial support.

Sources

Ask CASRAI · free to try

Ask about this story

2 free questions a day, no account.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →